Phase 1 N=14 An Investigational Study of Hydrocortisone
Adrenal Insufficiency
Primary: Maximum Serum Concentration (Cmax) — 940.012; 896.489; 1563.479 nmol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=135 Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
Delirium · Cognitive Impairment · Post-traumatic Stress Disorder
Primary: Efficacy of Low-dose Haloperidol in Reducing Delirium Incidence — 15; 19 Participants
Phase 2 N=10 UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Multiple Myeloma
Primary: Therapeutic Efficacy — 1 Participants
N/A N=1,096 Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides
Surveillance
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 26; 2 participants
Phase 2 N=23 A Study to Assess Biomarkers Impact on Participants Response to Erlotinib Treatment for First-line Non-Small Cell Lung Cancer With Endothelial Growth Factor Receptor (EGFR) Activating Mutations
Carcinoma，Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS), as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 387.000 days
Phase 3 N=121 Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions
Pancreatic Solid Lesions · Pancreatic Mass
Primary: Diagnostic Yield of Capillary Technique — 75.4 percentage of specimen
Phase 2 N=22 A Randomized Trial to Evaluate Ampyra for Gait Impairment in Parkinson's Disease
Parkinson's Disease
Primary: Change in Velocity — 0.03; 0.05 m/s
Phase 2 N=28 Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
AIDS
Primary: Number of Subjects With Frequency of Cluster of Differentiation 8 (CD8+) T Cells Expressing at Least One Cytokine to at Least 1, 2, 3 or All 4 Antigens — 1; 3; 0; 0…
N/A N=50 Post-bypass Prophylactic IVIG in Infants and Neonates
Hypogammaglobulinemia · Congenital Heart Disease
Primary: Post-Operative Infections — 9; 6; 21; 14 subjects — p=1
Phase 3 N=825 Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine
Acellular Pertussis · Tetanus · Diphtheria
Primary: Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids — 241; 250; 234; 269 Participants
Phase 2 N=11 Development of Ivermectin for Alcohol Use Disorders
Alcohol Use Disorder
Primary: Heart Rate — 64.57; 68.36; 66.82; 62.82 BPM — p=0.0563
Phase 2 N=400 A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
Breast Cancer
Primary: Percentage of Participants With at Least One Event of New York Heart Association (NYHA) Class III or IV Heart Failure During the Neoadjuvant Treatment Period — 1.5; 0…
Phase 2 N=13 Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Sickle Cell Disease · Priapism
Primary: Greater Than or Equal to a 50% Reduction in Priapic Episodes — 3; 3 Number of participants — p=1
Phase 4 N=21 Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
Cystic Fibrosis · Cystic Fibrosis Pulmonary Exacerbation · Pseudomonas Aeruginosa Infection
Primary: Ceftolozane Clearance — 4.76 Liters per hour
N/A N=122 The Effect of Priming of Questionnaire Content on Grip Strength in Patients With Hand and Upper Extremity Illness
Hand and Upper Extremity Illness
Primary: Pain Catastrophizing Scale (PCS) — 8.2 units on a scale